Dr. Paula D. Ryan, MD, PHD
Medical Oncology (Medical Oncology Physician)
9200 Pinecroft Dr Ste 450
Shenandoah, TX 77380
Who else practices at this address →
Montgomery County is a federal mental health shortage area. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Rochester School of Medicine and Dentistry (1994)
- Years since graduation
- 32
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 307
Licensed in Texas since 2014, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1994Medical school: University of Rochester School of Medicine and Dentistry
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
TX license Q0553 (first issued 2014; active) · MA license 205016 · PA license MD441313 -
Internal Medicine Physician
MA license 205016
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Memorial Hermann Hospital System Houston, TX
- Houston Methodist the Woodlands Hospital The Woodlands, TX
- Memorial Hermann Northeast Hospital Humble, TX
- HCA Houston Healthcare Conroe Conroe, TX
- Tops Surgical Specialty Hospital Houston, TX
Medical groups
- Texas Oncology PA (1,014 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 307
- Services billed
- 78,035
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 17,850 | 28 |
| Injection, pembrolizumab, 1 mg | 9,400 | 15 |
| Injection, fosaprepitant, 1 mg | 8,700 | 19 |
| Injection, dexamethasone sodium phosphate, 1 mg | 943 | 30 |
| Injection, palonosetron hcl, 25 mcg | 620 | 21 |
| Established patient office or other outpatient visit, 20-29 minutes | 250 | 181 |
| Injection of additional new drug or substance into vein | 171 | 34 |
| Administration of chemotherapy into vein, 1 hour or less | 162 | 48 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 129 | 27 |
| Blood test, comprehensive group of blood chemicals | 118 | 45 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Anastrozole Other prescribers in Shenandoah, TX | 738 |
| Letrozole Other prescribers in Shenandoah, TX | 152 |
| Tamoxifen Citrate Other prescribers in Shenandoah, TX | 49 |
| Ibrance (palbociclib) | 40 |
| Exemestane | 28 |
| Verzenio (abemaciclib) | 27 |
| Dexamethasone Other prescribers in Shenandoah, TX | 16 |
| Gabapentin Other prescribers in Shenandoah, TX | 14 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Shenandoah, TX | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 21 payments worth $1,413 in total to this clinician.
| Novartis Pharmaceuticals Corporation | $1,097 |
|---|---|
| Tempus Ai, Inc | $208 |
| Daiichi Sankyo Inc. | $77.99 |
| Eisai Inc. | $15.66 |
| Amneal Pharmaceuticals LLC | $14.12 |
| Long term medical supply or device loan | $1,097 |
|---|---|
| Food and Beverage | $238 |
| Education | $77.99 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation Feb 21, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Mar 26, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation May 15, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Apr 24, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Jun 12, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Jul 25, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Aug 21, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Oct 23, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Nov 26, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Dec 30, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
All 12 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation Dec 30, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Nov 26, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Oct 23, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Daiichi Sankyo Inc. Oct 20, 2025 | Education Enhertu · ONCOLOGY · in-kind | $77.99 |
| Novartis Pharmaceuticals Corporation Sep 19, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Aug 21, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Jul 25, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Jun 12, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation May 15, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Apr 24, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Mar 26, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Feb 21, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $315,099 in research payments for these studies, mostly to the institutions running them.
- Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09)
AstraZeneca Pharmaceuticals LP - Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer
Eli Lilly and Company · Active, not recruiting · NCT03155997 - A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
Eli Lilly and Company · Active, not recruiting · NCT04975308
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.